Peptide Blends
Eyeliss
Dipeptide-2 + Palmitoyl Tetrapeptide-7 + Hesperidin
1 min read · Updated July 27, 2026 · 1 references
Curated by PeptideInfo Wikilast reviewed how we verify
Eyeliss is included for complete PeptideGuide catalog coverage. Identity, evidence, regulatory status and safety claims are awaiting independent verification.
Evidence: Catalog coverage only; independent identity, evidence and regulatory review is still pending.
- Catalog-coverage record; not an independently verified monograph
- PeptideGuide dosing, safety and efficacy claims are not reproduced as facts
- Noindexed until identity and primary sources pass editorial review
Eyeliss is included for complete PeptideGuide catalog coverage. Identity, evidence, regulatory status and safety claims are awaiting independent verification.
Why this page exists
Eyeliss appears in the live PeptideGuide compound database and was absent from PeptideInfo when the coverage audit began. This page closes that catalog gap without converting a secondary-source claim into medical fact.
Catalog-coverage record; not an independently verified monograph
PeptideGuide dosing, safety and efficacy claims are not reproduced as facts. Noindexed until identity and primary sources pass editorial review.
Source identity
The imported source identifies this record as Eyeliss and expands the name as Dipeptide-2 + Palmitoyl Tetrapeptide-7 + Hesperidin. PeptideGuide places it in its Cosmetics category and applies the source label standard. Those labels describe the imported record, not PeptideInfo’s independent conclusion.
Source record ID: eyeliss. Snapshot row: 164.
What is withheld
The source snapshot contains the following claim fields: mechanism, dosing, safety rating, half-life, claimed benefits, side effects, regulatory/development label, blend components. Their values remain in quarantine and are intentionally not repeated here as dosing, safety, mechanism, efficacy or approval guidance.
Editorial next step
Editorial lane: scope-review-blend. The page can leave review-pending status only after exact identity is resolved and relevant regulator records or primary literature replace the external source claims.
References
- 1.PeptideGuide compound database — discovery source only source
Frequently asked questions
- What is Eyeliss?
- Eyeliss is included for complete PeptideGuide catalog coverage. Identity, evidence, regulatory status and safety claims are awaiting independent verification.
- Is Eyeliss approved as a medicine, and where?
- Eyeliss is included for catalog coverage, but its regulatory status has not yet been independently verified. The page does not imply approval or safe use.
- What is Eyeliss studied for?
- Eyeliss is most often discussed in the context of peptideguide source catalog — verification pending. Being studied for an area does not mean it is proven or approved for it.
- Does Eyeliss have human clinical trials?
- Our review has not yet established whether Eyeliss has relevant human evidence. The source record is published without presenting PeptideGuide claims as facts.
Educational disclaimer. This article summarizes published research for informational purposes and is not medical advice. Eyeliss is a catalog record whose identity, evidence and regulatory status have not yet been independently verified; the page does not claim approval, safety or suitability for use. Consult a qualified healthcare professional before making health decisions.